Sign inCreate account

Report workspace tools

NCT00687882COMPLETEDanonymous

Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children

Sponsor

Source record

Johns Hopkins All Children's Hospital

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Venous Thrombosis in Children

Indication / condition

AI-normalized

Venous Thrombosis

Intervention

Source record

Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention, No Intervention

Source & freshness

Source record

NCT ID

NCT00687882

Original source

ClinicalTrials.gov

Source last updated

Jun 18, 2025

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00687882

Title

Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children

Sponsor

Johns Hopkins All Children's Hospital

Status

COMPLETED

Phase

PHASE3

Condition raw

Venous Thrombosis

Condition normalized

Venous Thrombosis

Modality raw

Venous Thrombosis

Modality normalized

monoclonal antibody

Target raw

Venous Thrombosis in Children

Target normalized

Venous Thrombosis in Children

Interventions

Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention, No Intervention

Public preview

Source record

The Kids-DOTT trial evaluates the non-inferiority of a shortened duration (6 weeks) versus conventional duration (3 months) of anticoagulation therapy in children with first-episode acute venous thrombosis. The study aims to enroll 750 children across 40 centers, focusing on safety and efficacy outcomes related to recurrent venous thromboembolism (VTE) and bleeding.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00687882

Status

COMPLETED

Phase

PHASE3

Sponsor

Johns Hopkins All Children's Hospital

Executive brief

Investment-Ready Snapshot

The Kids-DOTT trial evaluates the non-inferiority of a shortened duration (6 weeks) versus conventional duration (3 months) of anticoagulation therapy in children with first-episode acute venous thrombosis. The study aims to enroll 750 children across 40 centers, focusing on safety and efficacy outcomes related to recurrent venous thromboembolism (VTE) and bleeding.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 18, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00687882

Indication

Venous Thrombosis

Modality

monoclonal antibody

Target

Venous Thrombosis in Children

Intervention

Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of anticoagulant therapy, No Intervention, No Intervention

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.